Arrowhead Pharmaceuticals, Inc. (0HI3.L)
USD 13.14
(-0.02%)
USD 13.14
(-0.02%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 478.39 Million USD | -18.36% |
| 2022 | 585.97 Million USD | 94.47% |
| 2021 | 301.32 Million USD | 396.22% |
| 2020 | 60.72 Million USD | -42.61% |
| 2019 | 105.8 Million USD | 546.4% |
| 2018 | 16.36 Million USD | -29.31% |
| 2017 | 23.15 Million USD | -30.16% |
| 2016 | 33.15 Million USD | 46.39% |
| 2015 | 22.64 Million USD | 34.55% |
| 2014 | 16.83 Million USD | 45.16% |
| 2013 | 11.59 Million USD | 50.21% |
| 2012 | 7.71 Million USD | 132.19% |
| 2011 | 3.32 Million USD | -22.26% |
| 2010 | 4.27 Million USD | 50.35% |
| 2009 | 2.84 Million USD | -42.57% |
| 2008 | 4.95 Million USD | 45.83% |
| 2007 | 3.39 Million USD | 16.3% |
| 2006 | 2.92 Million USD | 185.16% |
| 2005 | 1.02 Million USD | 48.48% |
| 2004 | 689.69 Thousand USD | 617.11% |
| 2003 | 96.17 Thousand USD | -94.04% |
| 2002 | 1.61 Million USD | 19.5% |
| 2001 | 1.35 Million USD | 13.1% |
| 2000 | 1.19 Million USD | 10.75% |
| 1999 | 1.07 Million USD | -60.24% |
| 1998 | 2.71 Million USD | 1.07% |
| 1997 | 2.68 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 544.78 Million USD | 18.5% |
| 2024 Q1 | 452.57 Million USD | -5.4% |
| 2024 Q2 | 459.74 Million USD | 1.58% |
| 2023 Q3 | 413.87 Million USD | -2.89% |
| 2023 Q2 | 426.2 Million USD | -13.92% |
| 2023 FY | 478.39 Million USD | -18.36% |
| 2023 Q1 | 495.11 Million USD | -15.51% |
| 2023 Q4 | 478.39 Million USD | 15.59% |
| 2022 Q1 | 265.97 Million USD | -11.73% |
| 2022 FY | 585.97 Million USD | 94.47% |
| 2022 Q4 | 585.97 Million USD | 111.08% |
| 2022 Q3 | 277.6 Million USD | 10.46% |
| 2022 Q2 | 251.3 Million USD | -5.52% |
| 2021 Q3 | 298.03 Million USD | -4.24% |
| 2021 Q4 | 301.32 Million USD | 1.1% |
| 2021 Q2 | 311.24 Million USD | 595.07% |
| 2021 FY | 301.32 Million USD | 396.22% |
| 2021 Q1 | 44.77 Million USD | -26.26% |
| 2020 Q3 | 63.14 Million USD | -6.47% |
| 2020 FY | 60.72 Million USD | -42.61% |
| 2020 Q1 | 88.07 Million USD | -16.76% |
| 2020 Q2 | 67.51 Million USD | -23.35% |
| 2020 Q4 | 60.72 Million USD | -3.83% |
| 2019 Q3 | 111.15 Million USD | -16.61% |
| 2019 Q4 | 105.8 Million USD | -4.81% |
| 2019 Q1 | 169.44 Million USD | 935.18% |
| 2019 FY | 105.8 Million USD | 546.4% |
| 2019 Q2 | 133.3 Million USD | -21.33% |
| 2018 Q2 | 13.28 Million USD | -26.29% |
| 2018 FY | 16.36 Million USD | -29.31% |
| 2018 Q3 | 11.14 Million USD | -16.11% |
| 2018 Q4 | 16.36 Million USD | 46.89% |
| 2018 Q1 | 18.02 Million USD | -22.17% |
| 2017 Q4 | 23.15 Million USD | -9.34% |
| 2017 FY | 23.15 Million USD | -30.16% |
| 2017 Q3 | 25.53 Million USD | -23.84% |
| 2017 Q2 | 33.53 Million USD | -28.72% |
| 2017 Q1 | 47.04 Million USD | 41.92% |
| 2016 Q2 | 20.68 Million USD | 8.78% |
| 2016 FY | 33.15 Million USD | 46.39% |
| 2016 Q4 | 33.15 Million USD | 26.98% |
| 2016 Q1 | 19.01 Million USD | -16.04% |
| 2016 Q3 | 26.1 Million USD | 26.24% |
| 2015 Q3 | 14.44 Million USD | -20.55% |
| 2015 FY | 22.64 Million USD | 34.55% |
| 2015 Q1 | 16.42 Million USD | -2.4% |
| 2015 Q4 | 22.64 Million USD | 56.77% |
| 2015 Q2 | 18.18 Million USD | 10.68% |
| 2014 Q3 | 10.81 Million USD | -17.47% |
| 2014 Q4 | 16.83 Million USD | 55.63% |
| 2014 FY | 16.83 Million USD | 45.16% |
| 2014 Q1 | 11.78 Million USD | 1.62% |
| 2014 Q2 | 13.1 Million USD | 11.22% |
| 2013 FY | 11.59 Million USD | 50.21% |
| 2013 Q1 | 7.62 Million USD | -1.2% |
| 2013 Q3 | 8.18 Million USD | -5.5% |
| 2013 Q4 | 11.59 Million USD | 41.7% |
| 2013 Q2 | 8.65 Million USD | 13.53% |
| 2012 FY | 7.71 Million USD | 132.19% |
| 2012 Q3 | 8.03 Million USD | -5.58% |
| 2012 Q1 | 7.31 Million USD | 119.99% |
| 2012 Q4 | 7.71 Million USD | -3.99% |
| 2012 Q2 | 8.51 Million USD | 16.42% |
| 2011 Q2 | 3.01 Million USD | -61.85% |
| 2011 Q4 | 3.32 Million USD | 22.19% |
| 2011 FY | 3.32 Million USD | -22.26% |
| 2011 Q1 | 7.9 Million USD | 84.79% |
| 2011 Q3 | 2.72 Million USD | -9.75% |
| 2010 Q1 | 2.57 Million USD | -9.3% |
| 2010 FY | 4.27 Million USD | 50.35% |
| 2010 Q4 | 4.27 Million USD | -16.81% |
| 2010 Q3 | 5.14 Million USD | 125.49% |
| 2010 Q2 | 2.27 Million USD | -11.63% |
| 2009 Q4 | 2.84 Million USD | -36.58% |
| 2009 Q3 | 4.48 Million USD | -54.06% |
| 2009 Q1 | 10.39 Million USD | 109.78% |
| 2009 FY | 2.84 Million USD | -42.57% |
| 2009 Q2 | 9.76 Million USD | -6.05% |
| 2008 Q1 | 2.78 Million USD | -18.05% |
| 2008 Q2 | 2.79 Million USD | 0.36% |
| 2008 Q3 | 3.05 Million USD | 9.38% |
| 2008 Q4 | 4.95 Million USD | 62.1% |
| 2008 FY | 4.95 Million USD | 45.83% |
| 2007 Q1 | 1.01 Million USD | -65.23% |
| 2007 Q3 | 2.94 Million USD | 156.51% |
| 2007 Q4 | 3.39 Million USD | 15.52% |
| 2007 FY | 3.39 Million USD | 16.3% |
| 2007 Q2 | 1.14 Million USD | 12.9% |
| 2006 FY | 2.92 Million USD | 185.16% |
| 2006 Q1 | 1.45 Million USD | 42.23% |
| 2006 Q4 | 2.92 Million USD | 68.93% |
| 2006 Q3 | 1.72 Million USD | -33.24% |
| 2006 Q2 | 2.58 Million USD | 77.77% |
| 2005 Q1 | 351.93 Thousand USD | -48.97% |
| 2005 FY | 1.02 Million USD | 48.48% |
| 2005 Q4 | 1.02 Million USD | 3.16% |
| 2005 Q3 | 992.71 Thousand USD | 71.39% |
| 2005 Q2 | 579.22 Thousand USD | 64.58% |
| 2004 Q1 | 20.33 Thousand USD | -78.86% |
| 2004 Q3 | 372.96 Thousand USD | 870.9% |
| 2004 FY | 689.69 Thousand USD | 617.11% |
| 2004 Q4 | 689.69 Thousand USD | 84.92% |
| 2004 Q2 | 38.41 Thousand USD | 88.94% |
| 2003 Q4 | 96.17 Thousand USD | -94.66% |
| 2003 FY | 96.17 Thousand USD | -94.04% |
| 2003 Q1 | 1.64 Million USD | 1.81% |
| 2003 Q2 | 1.74 Million USD | 6.1% |
| 2003 Q3 | 1.8 Million USD | 3.23% |
| 2002 FY | 1.61 Million USD | 19.5% |
| 2002 Q4 | 1.61 Million USD | 2.75% |
| 2002 Q2 | 1.42 Million USD | 0.82% |
| 2002 Q1 | 1.41 Million USD | 4.85% |
| 2002 Q3 | 1.57 Million USD | 10.02% |
| 2001 FY | 1.35 Million USD | 13.1% |
| 2001 Q1 | 1.22 Million USD | 2.25% |
| 2001 Q2 | 1.26 Million USD | 3.93% |
| 2001 Q4 | 1.35 Million USD | 3.79% |
| 2001 Q3 | 1.3 Million USD | 2.55% |
| 2000 Q3 | 1.23 Million USD | 4.66% |
| 2000 Q4 | 1.19 Million USD | -2.95% |
| 2000 FY | 1.19 Million USD | 10.75% |
| 2000 Q2 | 1.17 Million USD | 4.58% |
| 2000 Q1 | 1.12 Million USD | 2.22% |
| 1999 Q2 | 2.7 Million USD | 0.0% |
| 1999 Q4 | 1.1 Million USD | 10.0% |
| 1999 Q3 | 1 Million USD | -62.96% |
| 1999 FY | 1.07 Million USD | -60.24% |
| 1998 Q2 | 2.7 Million USD | 0.0% |
| 1998 Q3 | 2.7 Million USD | 0.0% |
| 1998 Q4 | 2.9 Million USD | 7.41% |
| 1998 FY | 2.71 Million USD | 1.07% |
| 1997 FY | 2.68 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | -37.635% |
| Codexis, Inc. | 49.94 Million USD | -857.814% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -888.368% |
| Organovo Holdings, Inc. | 2.74 Million USD | -17308.661% |